Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF^V600-mutated melanoma.

ABSTRACT:

Background

BRAF inhibitors are approved in BRAF^V600-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim-Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent vemurafenib given in the AcSé vemurafenib basket study to patients with various BRAF-mutated advanced tumours other than BRAF^V600-mutated melanoma and NSCLC.

Patients and methods

Patients with advanced tumours other than BRAF^V600E melanoma and progressing after standard treatment were eligible for inclusion in nine cohorts (including a miscellaneous cohort) and received oral vemurafenib 960 mg two times daily. The primary endpoint was the objective response rate (ORR) estimated with a Bayesian design. Th

SUBMITTER: Blay JY 

PROVIDER: S-EPMC10774964 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature